Compare Abbott Laboratories (ABT) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs H2O America — how do they compare? Abbott Laboratories trades at $111.11 (market cap $187.95B), while H2O America trades at $62.36 (market cap $2.61B). The key difference: Abbott Laboratories is far larger — about 72× H2O America's market cap, and H2O America pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| ABT | HTO | |
|---|---|---|
Market Cap | $187.95B | $2.61B |
Sector | Health | Technology |
52-Week High | $136.62 | $65.43 |
52-Week Low | $82.57 | $44.44 |
Enterprise Value | $214.96B | $4.40B |
Dividend Yield | 2.32% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
HTO trades at $62.39, up 1.87% today, with a bullish technical signal from moving averages and support near $61. Recent earnings show Q2 2026 adjusted EPS of $0.72 beating expectations, while Q4 2025 missed. Revenue grew to $829 million in 2026, with a net margin of 12.9%. The company announced a $0.44 dividend payable September 1, 2026, and faces execution risks from acquisitions like Quadvest, which diluted shares.
The stock offers upside to the $69.50 consensus price target, supported by strong analyst buy ratings (83%) and institutional accumulation. Risks include acquisition integration challenges and EPS pressure from equity issuance. Fundamentals remain solid with steady profitability, but investors should monitor debt levels and dividend sustainability amid expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
